Dr. Brigitte Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and a clinical professor at Laval University School of Medicine. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.

Offer innovative treatments

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
+1 418-682-7511
brigitte.poirier@crchudeq... recherche.cms-cha.cha@sss...

Latest news

Data not available

22 entries « ‹ 2 of 3 › »

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzu D, McNally V, Douthwaite H, Ross G, Valagussa P

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Journal Article

Lancet Oncol, 17 (6), pp. 791-800, 2016, ISSN: 1470-2045.

Abstract | Links:

Diorio C, Provencher L, Morin J, Desbiens C, Poirier B, Poirier E, Hogue JC, Jacob S, Cote G

Is there an Upgrading to Malignancy at Surgery of Mucocele-Like Lesions Diagnosed on Percutaneous Breast Biopsy?

Journal Article

Breast J, 22 (2), pp. 173-9, 2016, ISSN: 1075-122X.

Abstract | Links:

Ennour-Idrissi K, Tetu B, Maunsell E, Poirier B, Montoni A, Rochette PJ, Diorio C

Association of Telomere Length with Breast Cancer Prognostic Factors.

Journal Article

PLoS ONE, 11 (8), pp. e0161903, 2016.

Abstract | Links:

Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzu D, de la Haba-Rodriguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

Journal Article

Ann Oncol, 26 (12), pp. 2429-36, 2015, ISSN: 0923-7534.

Abstract | Links:

Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Journal Article

J Clin Oncol, 33 (3), pp. 258-64, 2015, ISSN: 0732-183X.

Abstract | Links:

Lemieux J, Forget G, Brochu O, Provencher L, Cantin G, Desbiens C, Doyle C, Poirier B, Camden S, Durocher M

Evaluation of eligibility and recruitment in breast cancer clinical trials.

Journal Article

Breast, 23 (4), pp. 385-92, 2014, ISSN: 0960-9776.

Abstract | Links:

Poirier E, Desbiens C, Poirier B, Hogue JC, Lemieux J, Doyle C, Leblond AF, Cote I, Cantin G, Provencher L

Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.

Journal Article

Ann Pharmacother, 48 (4), pp. 447-55, 2014, ISSN: 1060-0280.

Abstract | Links:

Hogue JC, Morais L, Provencher L, Desbiens C, Poirier B, Poirier E, Jacob S, Diorio C

Characteristics associated with upgrading to invasiveness after surgery of a DCIS diagnosed using percutaneous biopsy.

Journal Article

Anticancer Res, 34 (3), pp. 1183-91, 2014, ISSN: 0250-7005.

Abstract | Links:

Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J

Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.

Journal Article

Clin Trials, 9 (5), pp. 652-9, 2012, ISSN: 1740-7745.

Abstract | Links:

Provencher L, Jacob S, Cote G, Hogue JC, Desbiens C, Poirier B, Raiche I, Le Regent L, Diorio C

Low frequency of cancer occurrence in same breast quadrant diagnosed with lobular neoplasia at percutaneous needle biopsy.

Journal Article

Radiology, 263 (1), pp. 43-52, 2012, ISSN: 0033-8419.

Abstract | Links:

22 entries « ‹ 2 of 3 › »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31

Recently finished projects

  • NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2020-01-31
Data provided by the Université Laval research projects registery